首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1624426

全球病毒灭活市场规模（依方法、产品、应用、最终用户、地区、范围和预测）

Global Viral Inactivation Market Size By Method, By Product, By Application, By End-User, By Geographic Scope And Forecast

出版日期: 2024年08月16日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

病毒灭活市场规模及预测

2023 年病毒灭活市场规模价值为 6.8391 亿美元，预计到 2031 年将达到 13.8946 亿美元，2024 年至 2031 年的复合年增长率为 9.27%。灭活病毒意味着破坏病毒的结构和遗传物质，使其失去传染性并阻止其复製或传播给他人。这可以透过多种方法实现，包括热处理、化学暴露和辐照。病毒灭活在医学、生物技术和医疗保健领域有着广泛的应用。药品製造中的病毒灭活可降低病毒污染的风险，保护源自动物或人体组织的生物製品，如疫苗、血液製品和重组蛋白。

此外，在医疗保健环境中，病毒灭活程序用于对医疗设备、表面和体液进行消毒，以限制病毒病原体的传播并防止疾病传播。

全球病毒灭活市场动态

主要市场驱动因子

慢性病发生率不断上升：

癌症、爱滋病毒和肝炎等慢性和危及生命的疾病的发生率不断上升，需要更有效的生物製药治疗。这种需求推动了病毒灭活市场的发展，因为它对于生物製剂和血浆衍生物的安全性和有效性至关重要。

严格的监理准则：

为了确保生物製药不受病毒污染，包括FDA和EMA在内的全球监管机构都对其生产制定了严格的规定。遵守这些法规需要使用病毒灭活技术，刺激市场扩张。

生物技术的进步：

生物技术和药物研发的快速发展，带动了疫苗、治疗性蛋白质和单株抗体等生物製药生产的扩大。这些产品需要病毒灭活以确保安全，从而推动了对病毒灭活技术的需求。

不断成长的生物製剂和生物相似药市场：

生物製剂和生物相似药的市场正在扩大，因为它们在治疗各种疾病方面很有效，并且需要严格的安全措施，包括病毒灭活。这种需求是病毒灭活市场的主要驱动力，因为产品安全对于监管部门批准和公众信心至关重要。

主要问题

成本高、资源密集：

实施病毒灭活技术耗时又费钱，需要在技术和合格人员方面进行大量投资。对于中小型製药和生技公司来说，这些高额投资是令人望而却步的，限制了它们在市场上的竞争力。

病毒突破的风险：

儘管有严格的病毒灭活程序，但仍有可能因变异或出现不熟悉的病毒而出现病毒。这种风险使得人们需要不断研究和开发以提高灭活方法的有效性，从而增加生物製药製造的复杂性和成本。

主要趋势

采用新技术：

病毒灭活市场扩大采用新技术，包括 UV-C 照射、高温、短时 (HTST) 处理和先进的化学方法。这些技术正在提高效率和安全性，克服传统方法的局限性，从而推动市场成长。

更重视自动化：

为了提高可重复性、消除人为错误和增加吞吐量，自动化病毒灭活程序的趋势日益增长。自动化还有助于遵守监管标准并使程序更有效率、更具成本效益。

进入新兴市场：

由于生物製药行业的扩张、医疗保健支出的增加以及对生物製剂安全性的日益担忧，病毒灭活市场正在扩展到新兴经济体。此次扩张为我们传统市场之外的新的市场成长前景开闢了机会。

进阶分析整合：

高级分析技术越来越多地被融入病毒灭活过程中，从而实现即时监测和控制。这种连结将使灭活方法更加准确和快捷，提高安全性和法规遵循性，同时也刺激市场创新。

Viral Inactivation Market size was valued at USD 683.91 Million in 2023 and is projected to reach USD 1389.46 Million by 2031 , growing at a CAGR of 9.27% from 2024 to 2031. Viral inactivation is the process of rendering viruses non-infectious by destroying their structure or genetic material, preventing them from replicating and infecting others. This is accomplished using a variety of ways, including heat treatment, chemical exposure, and irradiation. Viral inactivation has numerous applications, including medicines, biotechnology, and healthcare. Viral inactivation in pharmaceutical production protects biological products originating from animal or human tissues, such as vaccines, blood products, and recombinant proteins, by reducing the danger of viral contamination.

Additionally, in healthcare settings, viral inactivation procedures are used to sterilize medical equipment, surfaces, and bodily fluids, limiting viral pathogen transmission and preventing disease spread.

Global Viral Inactivation Market Dynamics

The key market dynamics that are shaping the Viral Inactivation Market include:

Key Market Drivers

Rising Prevalence of Chronic Diseases:

The rising prevalence of chronic and life-threatening diseases such as cancer, HIV, and hepatitis need more effective biopharmaceutical therapies. This need drives the Viral Inactivation Market since it is crucial to the safety and efficacy of biologics and plasma derivatives.

Stringent Regulatory Guidelines:

To ensure that biopharmaceutical products are free of viral contamination, regulatory bodies around the world, including the FDA and EMA, have established tight rules for their manufacturing. Complying with these rules involves the use of viral inactivation techniques, thereby fueling market expansion.

Advancements in Biotechnology:

Rapid advances in biotechnology and pharmaceutical R&D are resulting in greater manufacturing of biopharmaceuticals such as vaccines, therapeutic proteins, and monoclonal antibodies. These products require viral inactivation to ensure safety, which increases the demand for viral inactivation technology.

Growing Biologics and Biosimilars Market:

The rising market for biologics and biosimilars, driven by their efficacy in treating a variety of diseases, necessitates severe safety precautions, including viral inactivation. This need is a major driver of the Viral Inactivation Market, as product safety is critical for regulatory approval and public trust.

Key Challenges:

High Costs and Resource Intensity:

The execution of viral inactivation techniques is time-consuming and expensive, necessitating considerable investments in technology and qualified staff. These high expenditures are prohibitively expensive for smaller pharmaceutical and biotech companies, restricting their competitiveness in the market.

Risk of Viral Breakthrough:

Despite stringent viral inactivation procedures, there is always a possibility of viral emergence due to mutations or the presence of unfamiliar viruses. This risk needs continual research and development to improve the efficacy of inactivation methods, which increases the complexity and cost of biopharmaceutical manufacturing.

Key Trends:

Adoption of Novel Technologies:

The Viral Inactivation Market has experienced the use of novel technologies such as UV-C irradiation, high-temperature short-time (HTST) treatments, and sophisticated chemical approaches. These technologies increase efficiency and safety characteristics, overcoming the constraints of traditional approaches and boosting market growth.

Increased Focus on Automation:

There is a growing trend of automating viral inactivation operations to improve repeatability, eliminate human error, and boost throughput. Automation also helps to comply with regulatory standards, making procedures more efficient and cost-effective.

Expansion into Emerging Markets:

The Viral Inactivation Market is expanding into emerging economies, fueled by expanding biopharmaceutical industries, increased healthcare spending, and growing concern about biologics' safety. This expansion opens up new prospects for market growth beyond traditional markets.

Integration of Advanced Analytics:

Advanced analytics are increasingly being integrated into viral inactivation processes to provide real-time monitoring and control. This connection allows for more precise and fast inactivation methods, which improves safety profiles and regulatory compliance while also promoting market innovation.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Viral Inactivation Market Regional Analysis

Here is a more detailed regional analysis of the Viral Inactivation Market:

North America:

According to Verified Market Research, North America is estimated to dominate the Viral Inactivation Market over the forecast period. North America, particularly the United States, has a vast and sophisticated biopharmaceutical industry that leads in the development and production of vaccines, therapeutic proteins, and monoclonal antibodies. The magnitude and growth of this sector necessitate substantial viral inactivation methods, which drive regional demand.

The presence of severe regulatory organizations in the United States, such as the FDA, requires biopharmaceutical goods to meet stringent safety criteria, which include viral inactivation. This regulatory structure promotes high levels of compliance and the use of viral inactivation technology, hence promoting market dominance.

Furthermore, North America, particularly the United States, has one of the world's highest healthcare costs, indicating a significant investment in healthcare infrastructure, including innovative therapies and biopharmaceutical products. This investment encourages the use of sophisticated viral inactivation technologies, hence driving the market.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth potential in the market during the forecast period. The Asia Pacific region's biopharmaceutical industry is expanding rapidly, spurred by increased expenditures in biotechnology and healthcare infrastructure. This expansion needs sophisticated viral inactivation technologies, which drive market growth in countries such as China and India.

Governments and the corporate sector in Asia Pacific are considerably boosting healthcare spending to improve public health services and access to innovative treatments. This investment promotes the development and use of safe biopharmaceutical products, particularly those that require viral inactivation.

Furthermore, there is a growing awareness in the region about the necessity of biological safety and the dangers of virus contamination. This knowledge is increasing the demand for viral inactivation technologies to ensure the safety of vaccinations, therapeutic proteins, and other biologics.

Europe:

Europe has advanced healthcare systems with robust regulatory frameworks overseen by authorities such as the European Medicines Agency (EMA). These systems require rigorous safety criteria for biopharmaceutical goods, emphasizing the importance of successful viral inactivation to ensure patient safety and product efficacy.

Europe is home to considerable biopharmaceutical research and development efforts, which are funded by both public and private funding. This investment promotes innovation in viral inactivation technologies and procedures, hence contributing to regional market growth.

Furthermore, in Europe, biopharmaceutical businesses, research institutes, and technology providers are highly collaborative and form collaborations. These agreements promote the exchange of knowledge and technology, such as viral inactivation, which improves the region's ability to address viral safety in biopharmaceuticals.

Global Viral Inactivation Market: Segmentation Analysis

The Viral Inactivation Market is Segmented based on Method, Product, Application, End-User, and Geography.

Viral Inactivation Market, By Method

Solvent Detergent Method
Pasteurization
Others

Based on Method, the market is segmented into Solvent Detergent Method, Pasteurization, and Others. The solvent detergent method segment is estimated to grow at the highest CAGR within the Viral Inactivation Market due to its ability to inactivate encapsulated viruses while retaining the product's biological activity, making it a popular choice for the treatment of blood and plasma products, as well as certain biopharmaceuticals. The method's widespread acceptance can also be attributed to its simplicity, low cost, and comprehensive validation in assuring viral safety.

Viral Inactivation Market, By Product

Kits and Reagents
Services
Systems and Accessories

Based on Product, the market is segmented into Kits & Reagents, Services, and Systems & Accessories. The kits & reagents segment is estimated to dominate the Viral Inactivation Market due to their widespread application throughout all stages of pharmaceutical and biopharmaceutical production, including research and development, manufacturing, and quality control. Kits and reagents are critical for efficiently and effectively carrying out viral inactivation activities, providing a balance of usability, cost-effectiveness, and dependability. Their high demand is exacerbated by the requirement for continuous viral safety testing in the production of vaccines, medicinal proteins, and other biologics.

Viral Inactivation Market, By Application

Blood & Blood Products
Cellular & Gene Therapy Products
Stem Cell Products
Tissue & Tissue Products
Vaccines and Therapeutics

Based on Application, the market is segmented into Blood & Blood Products, Cellular & Gene Therapy Products, Stem Cell Products, Tissue & Tissue Products, and Vaccines & Therapeutics. The vaccines and therapeutics segment is estimated to dominate the market over the forecast period due to rising demand for vaccines and therapeutic medications, which is being driven by an increase in the global prevalence of chronic diseases and infectious outbreaks. The research and manufacturing of these products necessitate severe viral inactivation techniques to ensure safety and efficacy, making this market an important user of viral inactivation technology. Furthermore, continued efforts to improve vaccine development, particularly in response to new infectious illnesses, as well as increased investment in biopharmaceutical R&D, help to drive the segment's importance.

Viral Inactivation Market, By End-User

Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic Research Institutes
Others

Based on End-User, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, and Others. The pharmaceutical & biotechnology companies segment is estimated to dominate the market over the forecast period due to these companies' critical roles in the development, production, and commercialization of biopharmaceuticals such as vaccines, therapeutic proteins, and monoclonal antibodies, all of which require stringent viral inactivation processes to ensure safety and efficacy. The continued rise of biopharmaceutical research and development, combined with increased investments in biologic drug discovery, is driving demand for viral inactivation technologies in this market.

Key Players

The "Global Viral Inactivation Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Merck KGaA, Danaher Corporation, Sartorius AG, Charles River Laboratories, Clean Cells, Rad Source Technologies, Texcell, Viral Inactivated Plasma Systems SA, WuXi PharmaTech, Parker Hannifin Corporation, SGS SA, Thermo Fisher Scientific, Bio-Rad Laboratories, GE Healthcare, MilliporeSigma, Lonza Group, and Catalent.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Viral Inactivation Market Recent Developments
In May 2022, Pall Corporation established a partnership with RD-Biotech to produce vast volumes of Good Manufacturing Practice (GMP)-grade plasmid DNA (pDNA). The partnership seeks to fulfill the growing demand for gene and mRNA-based therapeutics, particularly for COVID-19 vaccine development.
In January 2021, Akron Biotechnology announced an exclusive global deal with Octapharma to manufacture virally inactivated Human AB Serum derived from Octaplas(R) for cell therapy. This alliance intends to improve the safety of human serum against viruses, particularly COVID-19, and support research and development for commercialization.

1 INTRODUCTION OF GLOBAL VIRAL INACTIVATION MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL VIRAL INACTIVATION MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL VIRAL INACTIVATION MARKET, BY METHOD

5.1 Overview
5.2 Solvent Detergent Method
5.3 Pasteurization
5.4 Others

6 GLOBAL VIRAL INACTIVATION MARKET, BY PRODUCT

6.1 Overview
6.2 Kits and Reagents
6.3 Services
6.4 Systems and Accessories

7 GLOBAL VIRAL INACTIVATION MARKET, BY APPLICATION

7.1 Overview
7.2 Blood & Blood Products
7.3 Cellular & Gene Therapy Products
7.4 Stem Cell Products
7.5 Tissue & Tissue Products
7.6 Vaccines and Therapeutics

8 GLOBAL VIRAL INACTIVATION MARKET, BY END-USER

8.1 Overview
8.2 Pharmaceutical and Biotechnology Companies
8.3 Contract Research Organizations
8.4 Academic Research Institutes
8.5 Others

9 GLOBAL VIRAL INACTIVATION MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL VIRAL INACTIVATION MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Sartorius AG
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Clean Cells
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Danaher Corporation
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Charles River Laboratories
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Merck KGaA
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Rad Source Technologies
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Parker Hannifin Corporation
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Viral Inactivated Plasma Systems SA
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 SGS SA
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 Texcell
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments

12 Appendix

12.1 Related Research

02-2729-4219

+886-2-2729-4219

License/价格

全球病毒灭活市场规模（依方法、产品、应用、最终用户、地区、范围和预测）

Global Viral Inactivation Market Size By Method, By Product, By Application, By End-User, By Geographic Scope And Forecast

病毒灭活市场规模及预测

全球病毒灭活市场动态

主要市场驱动因子

目录

第 1 章全球病毒灭活市场简介

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

第 4 章全球病毒灭活市场展望

第 5 章全球病毒灭活市场（依方法） 概述 溶剂清洗法 巴斯德消毒法 其他

第6章 全球病毒灭活市场（依产品）

第 7 章全球病毒灭活市场（依应用）

第 8 章全球病毒灭活市场（依最终用户划分）

第 9 章全球病毒灭活市场（按地区） 概述 北美洲 美国 加拿大 墨西哥 欧洲 德国 英国 法国 其他欧洲国家 亚太地区 中国 日本 印度 其他亚太地区 世界其他地区 拉丁美洲 中东和非洲

第 10 章全球病毒灭活市场的竞争格局

第 11 章 公司简介

第 12 章附录

Viral Inactivation Market Size And Forecast